BRAF and non-small cell lung carcinoma: Using three large‐scale NSCLC or LUAD cohorts (n = 27,413 in total), we identified 853 BRAF‐mutated patients, 28 (0.10%) of whom carried G469V and 79 (0.29%) carried G469A, analyzed the demographic, clinical, and molecular features of the G469‐mutated patients, and provided structural modeling evidence supporting direct binding of G469A with gefitinib, an EGFR TKI.